Filing Flows › Comparisons › RAPP vs LAB
Rapport Therapeutics vs Standard Biotools: RAPP and LAB compared
Rapport Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $19.4M for Standard Biotools (Q3 2026). Standard Biotools is more profitable, with an operating margin of -102.0% against -121.1%.
Where the money goes: RAPP and LAB
Rapport Therapeutics (RAPP) · Q1 2026
Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.
Standard Biotools (LAB) · Q3 2026
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Rapport Therapeutics (RAPP) | Standard Biotools (LAB) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q3 2026 |
| Revenue | $20.0M | $19.4M |
| Revenue growth, Y/Y | — | -0.9% |
| Operating margin | -121.1% | -102.0% |
| Net earnings | −$19.9M | $13.5M |
| Net margin | -99.3% | 69.6% |
| Operating cash flow | −$13.1M | −$6.2M |
Where the revenue comes from
Standard Biotools
- Product: $14.3M (74%)
- Services and Other Revenue: $5.1M (26%)
Questions
Which is bigger, Rapport Therapeutics or Standard Biotools?
Rapport Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $19.4M for Standard Biotools (Q3 2026).
Is Rapport Therapeutics or Standard Biotools growing faster?
Standard Biotools is more profitable, with an operating margin of -102.0% against -121.1%.
More: Rapport Therapeutics earnings · how Rapport Therapeutics makes money · Standard Biotools earnings · how Standard Biotools makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 7, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.